NCT06990893 Comparison of the Analgesic Effect of Oliceridine Versus Morphine or Sufentanil for Postoperative Analgesia in Lumbar Surgeries: a Randomized Control Trial
| NCT ID | NCT06990893 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Anqing Municipal Hospital |
| Condition | Sufentanil |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2025-06-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Objective: This study aimed to compare the efficacy and safety of oliceridine versus morphine and sufentanil for postoperative analgesia following elective lumbar spine surgery. Methods: In this randomized, controlled trial, 90 patients scheduled for lumbar spine surgery were allocated in a 1:1:1 ratio to receive postoperative intravenous patient-controlled analgesia (PCIA) with either oliceridine (Group O，1.5mg oliceridine for loading dose， 0.5mg/kg oliceridine for PICA), morphine (Group M，4mg morphine for loading dose，1.5mg/kg morphine for PICA), or sufentanil (Group S，4ug sufentanil for loading dose，1.5ug/kg sufentanil for PICA). The primary outcome was the movement Visual Analogue Scale (VAS) score at 6 hours postoperatively. Secondary outcomes included resting and movement VAS scores, ramsay sation score at 0.5, 2, 6, 12, 24, and 48 hours postoperatively (excluding the motor VAS score at 6 hours postoperatively); number of PCIA demands and rescue analgesic requirements within 48 hours; hemodynamic parameters at 5, 10, 15, 30, and 60 minutes after administration of the initial loading dose. The incidence of adverse events within 48 hours postoperatively, such as nausea and vomiting, somnolence, respiratory depression, or pruritus.
Eligibility Criteria
Inclusion Criteria: * Lumbar spine surgery with ASA grades I-III * Aged 18-65 years * Ethically, the patient voluntarily accepted this trial and signed the informed consent form Exclusion Criteria: * Severe respiratory and circulatory system diseases * Nervous system disease * Mental and psychological disorders * Abnormal liver and kidney functions * Participated in another drug clinical research within the past 30 days
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06990893 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Sufentanil. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06990893 currently recruiting?
Yes, NCT06990893 is actively recruiting participants. Contact the research team at 348092640@qq.com for enrollment information.
Where is the NCT06990893 trial being conducted?
This trial is being conducted at Anqing, China.
Who is sponsoring the NCT06990893 clinical trial?
NCT06990893 is sponsored by Anqing Municipal Hospital. The trial plans to enroll 90 participants.